Celiac Disease Treatment Market Size, Share and Trends 2025 to 2034

The market is witnessing global traction, with North America and Asia Pacific emerging as key growth regions. North America's growth is supported by high disease awareness, diagnostic infrastructure, and research funding, while Asia Pacific is seeing rising diagnoses due to improving healthcare access and changing dietary patterns. In Europe, market growth is strongly underpinned by government-backed healthcare initiatives, robust diagnostic networks, and awareness campaigns aimed at early identification and management of celiac disease.

The celiac disease treatment space is supported by a robust and innovation-driven startup ecosystem. Notably, Beyond Celiac Investments (BCI), a strategic advocacy initiative, is channeling capital into therapeutic development. Biotech startups such as ImmunogenX, Glutenon, and Calypso Biotech are actively pursuing peptide-based drugs and biologics, and many are advancing through various stages of clinical trials. These early-stage innovators are pushing the boundaries of treatment beyond traditional dietary management, aiming to offer disease-modifying therapies that could significantly reshape the market landscape.

The immune modulators segment led the market with a 40% share in 2024. This dominance stems from the fact that celiac disease is an autoimmune disorder, triggered by the ingestion of gluten-containing foods. Immune modulator therapies are specifically designed to regulate or suppress the body's abnormal immune response to gluten, thereby addressing the root cause of the disease rather than just managing its symptoms. These drugs offer the potential for more definitive, long-term therapeutic outcomes and are gaining traction as research shifts toward disease-modifying treatments beyond dietary control.

The enzyme therapy segment is expected to witness the fastest growth during the forecast period. This growth is primarily driven by its potential to mitigate the effects of gluten ingestion, offering an alternative to the strict, lifelong gluten-free diet currently required for managing celiac disease. Enzyme-based treatments are gaining traction within the medical community for their ability to break down immunogenic gluten peptides, thereby reducing intestinal damage and improving patient quality of life, especially in cases of accidental gluten exposure.

The oral segment dominated the market, holding the largest share of 70% in 2024. This dominance is primarily attributed to the convenience, non-invasiveness, and broad availability of orally administered therapies. Oral treatments align with patient preferences for easy-to-use, self-managed options, particularly as awareness of gluten-related disorders grows. The increasing shift toward non-invasive therapeutic approaches for managing chronic conditions has significantly reinforced the demand for oral formulations, making this the most widely adopted route of administration across diverse demographics.

The injectable segment is expected to register the fastest CAGR over the forecast period. Growth in this segment is being driven by the emergence of novel biologics and immune-modulatory therapies, particularly for refractory or severe cases of celiac disease that do not respond adequately to dietary management alone. As these advanced therapies often require precise systemic delivery, injectable formulations are considered the most effective and clinically appropriate route, especially in controlled or hospital-based settings, contributing to their accelerating uptake.

The hospitals & clinics segment held the largest market share of 50% in 2024. This is largely due to the fact that hospitals and specialized clinics serve as primary points of diagnosis and treatment initiation. These facilities offer access to advanced therapeutic interventions such as enzyme therapies and biologics, particularly for moderate to severe or refractory cases. Additionally, the growing prevalence of celiac disease, coupled with the expansion of well-structured healthcare infrastructure globally, continues to support this segment’s growth.

The pharmacies & retail stores segment is expected to grow at the fastest CAGR during the forecast period. This growth is driven by the rising global demand for gluten-free products and the increased accessibility of over-the-counter supplements, enzyme therapies, and dietary aids through pharmacies and retail outlets. Pharmacies play a crucial role in supporting ongoing disease management, offering both prescription and non-prescription products essential for daily care. As awareness increases and product availability improves, this segment is expected to expand significantly, especially in urban and semi-urban areas.

The hospital pharmacies segment led the market, holding the largest share of 45% in 2024. The segment's dominance is due to the services provided by hospital pharmacies to diagnose and treat complex autoimmune diseases like celiac disease, helping manage them effectively with the support of healthcare professionals and ongoing research. Hospital pharmacies offer a comprehensive care approach, monitoring symptoms and changes in patients' responses throughout the treatment.

The online/e-commerce segment is expected to expand at the fastest CAGR during the foreseeable period of 2025-2034. The segment is expanding significantly due to the increasing preference among consumers and healthcare professionals for a wider product selection and competitive pricing on medications for celiac disease treatment. E-commerce platforms offer exactly the same benefits, fueling the segment's growth.

Asia Pacific is expected to experience the fastest growth in the upcoming period. The regional market growth is driven by a convergence of factors, including rising awareness of gluten-related disorders, increased healthcare expenditure, and government-backed health policies aimed at strengthening diagnostic and treatment capabilities. The region is witnessing significant advancements in diagnostic technologies, such as genetic testing and antibody-based detection, which are enabling earlier and more accurate identification of celiac disease.

Additionally, sustained investment in healthcare infrastructure is expanding access to medical services, particularly in emerging economies. This expansion is facilitating wider screening, improved patient reach, and enhanced disease management strategies. The ongoing commercialization of advanced diagnostics and therapies further positions Asia Pacific as a high-growth market for celiac disease treatment over the next decade.

India Celiac Disease Treatment Market Trends

There is a significant surge in the consumption of gluten-free foods in India, driven by the rising incidence of celiac disease and growing awareness of the need for lifelong dietary management. In response, domestic manufacturers are actively launching new gluten-free products, particularly targeting health-conscious consumers and diagnosed patients in urban centers.

Additionally, there has been a noticeable improvement in diagnostic capabilities and public health awareness, with both the general population and healthcare professionals increasingly recognizing the symptoms and long-term risks associated with celiac disease. This evolving landscape is creating a favorable environment for market growth, especially in terms of product innovation, retail expansion, and early diagnosis initiatives.

Europe is expected to grow significantly due to increased awareness, the high prevalence of this health condition, and supportive government healthcare policies. Patient advocacy groups and public health campaigns, along with improved diagnostic technologies, forecast higher rates of celiac disease diagnosis across Europe.

Germany Celiac Disease Treatment Market Trends

Germany has a robust healthcare system that incorporates advanced diagnostic technologies and research. It includes celiac-specific antibodies and genetic markers. Additionally, the rapid growth of gluten-free products in German supermarkets, health stores, and restaurants highlights its well-developed efforts to combat celiac disease.